glp-1 regulations THE MICRODOSING PROGRAM Medicaid Coverage of and Spending

Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide

Oral semaglutide 25 mg (Wegovy pill) , FDA-approved December 22, 2025, is the first oral GLP-1 approved for chronic weight management

Acute treatment of diet-induced obese mice with labelled semaglutide has been shown to allow the drug to access circumventricular organs that lack a substantial blood brain barrier, including the area postrema (AP), median eminence (ME), vascular organ of the lamina terminalis (OV), and subfornical organ (SFO) (33)

Stand-Alone Options: Lumen Device : $399, including AI food log and nutrition coaching

Dryness and sensitivity: Some patches can damage your skin barrier, leading to peeling or localised pain